Comparative Pharmacology
Head-to-head clinical analysis: HYDROXOCOBALAMIN versus REDISOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXOCOBALAMIN versus REDISOL.
HYDROXOCOBALAMIN vs REDISOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxocobalamin is a precursor of methylcobalamin and adenosylcobalamin, which are essential cofactors for methionine synthase and methylmalonyl-CoA mutase. It facilitates the conversion of homocysteine to methionine and methylmalonyl-CoA to succinyl-CoA, and neutralizes cyanide by forming cyanocobalamin.
Hydroxocobalamin is a synthetic form of vitamin B12 that acts as a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis. It also binds to cyanide ions to form cyanocobalamin, which is excreted renally, thereby detoxifying cyanide.
1000 mcg intramuscularly once daily for 1 week, then weekly for 1 month, then monthly. For maintenance: 1000 mcg intramuscularly once monthly. Route: IM.
Cyanocobalamin 1000 mcg intramuscularly or subcutaneously once daily for 5-10 days, then 100-1000 mcg monthly for maintenance; intranasal: 500 mcg intranasally once weekly.
None Documented
None Documented
Terminal elimination half-life: ~26-31 days. After high-dose therapy, plasma levels decline more rapidly initially (α-phase half-life ~6 hours) due to distribution, followed by slow terminal elimination reflecting tissue release. Clinically, this supports monthly dosing for deficiency correction.
~50-100 minutes; prolonged in renal impairment
Primarily renal excretion (50-90% as unchanged drug). Biliary/fecal elimination accounts for <10%.
Primarily renal (50-80% as unchanged drug); minimal biliary/fecal
Category C
Category C
Vitamin B12 Supplement
Vitamin B12 Supplement